1.Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.
Federico COCCOLINI ; Luca CAMPANATI ; Fausto CATENA ; Valentina CENI ; Marco CERESOLI ; Jorge JIMENEZ CRUZ ; Marco LOTTI ; Stefano MAGNONE ; Josephine NAPOLI ; Diego ROSSETTI ; Pierandrea DE IACO ; Luigi FRIGERIO ; Antonio PINNA ; Ingo RUNNEBAUM ; Luca ANSALONI
Journal of Gynecologic Oncology 2015;26(1):54-61
OBJECTIVE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recently reported with favorable oncological outcomes as treatment of advanced epithelial ovarian cancer (EOC). The aim of this study was to demonstrate the feasibility of CRS+HIPEC with cisplatin and paclitaxel for the treatment of advanced EOC. METHODS: This is a prospective observational study of 54 patients, from April 2007 to October 2013, with primary or recurrent peritoneal carcinomatosis due to EOC. The mean age was 54.51+/-9.34. Thirty patients (59%) had primary EOC, and 24 patients (41%) had recurrent disease. RESULTS: Mean peritoneal cancer index was 10.11 (range, 0 to 28), complete cytoreduction (CC0) was achieved for 47 patients (87%), CC1 for seven patients (13%). Patients with suboptimal cytoreduction (CC2 and CC3) were not included in the study. The mean stay in intensive care unit was 4.73+/-5.51 days and the mean hospitalization time was 24.0+/-10.03 days. We did not observe any intraoperative death. Seven patients (13%) required additional operations. Three patients (5.6%) died within 30 days from the procedure. Severe complications were seen in 19 patients (35.2%). During the follow-up period, disease recurred in 33 patients (61.1%); the median disease-free survival time was 12.46 months and the median overall survival time was 32.91 months. CONCLUSION: CRS+HIPEC with cisplatin and paclitaxel for advanced EOC is feasible with acceptable morbidity and mortality. Additional follow-up and further studies are needed to determine the effects of HIPEC on long term survival.
Adult
;
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use
;
Cisplatin/administration & dosage/adverse effects
;
Combined Modality Therapy
;
Cytoreduction Surgical Procedures/adverse effects/methods
;
Feasibility Studies
;
Female
;
Humans
;
Hyperthermia, Induced/adverse effects/*methods
;
Infusions, Parenteral
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/drug therapy/surgery
;
Ovarian Neoplasms/*drug therapy/surgery
;
Paclitaxel/administration & dosage/adverse effects
;
Prospective Studies
;
Treatment Outcome
2.Generation of Organotypic Multicellular Spheres by Magnetic Levitation: Model for the Study of Human Hematopoietic Stem Cells Microenvironment
Claudia Camila MEJÍA-CRUZ ; Emilia BARRETO-DURÁN ; María Alejandra PARDO-PÉREZ ; María Camila JIMENEZ ; Julieth RINCÓN ; Karen VANEGAS ; Jorge Luis RODRÍGUEZ ; Luis Fernando JARAMILLO-GARCIA ; Juan Carlos ULLOA ; Rodolfo Martínez DÍAZ ; Efrain LEAL-GARCÍA ; Rafael PÉREZ-NÚÑEZ ; Alfonso BARRETO ; Viviana M RODRÍGUEZ-PARDO
International Journal of Stem Cells 2019;12(1):51-62
BACKGROUND AND OBJECTIVE: The characteristics of human hematopoietic stem cells are conditioned by the microenvironment of the bone marrow, where they interact with other cell populations, such as mesenchymal stem cells and endothelial cells; however, the study of this microenvironment is complex. The objective of this work was to develop a 3D culture system by magnetic levitation that imitates the microenvironment of human HSC. METHODS AND RESULTS: Human bone marrow-mesenchymal stem cells, umbilical cord blood-hematopoietic stem cells and a non-tumoral endothelial cell line (CC2811, Lonza®) were used to develop organotypic multicellular spheres by the magnetic levitation method. We obtained viable structures with an average sphericity index greater than 0.6, an average volume of 0.5 mm3 and a percentage of aggregation greater than 70%. Histological studies of the organotypic multicellular spheres used hematoxylin and eosin stains, and an evaluation of vimentin expression by means of immunohistochemistry demonstrated an organized internal structure without picnotic cells and a high expression of vimentin. The functional capacity of human hematopoietic stem cells after organotypic multicellular spheres culture was evaluated by multipotency tests, and it was demonstrated that 3D structures without exogenous Flt3L are autonomous in the maintenance of multipotency of human hematopoietic stem cells. CONCLUSIONS: We developed organotypic multicellular spheres from normal human cells that mimic the microenvironment of the human hematopoietic stem cells. These structures are the prototype for the development of complex organoids that allow the further study of the biology of normal human stem cells and their potential in regenerative medicine.
Biology
;
Bone Marrow
;
Coloring Agents
;
Endothelial Cells
;
Eosine Yellowish-(YS)
;
Hematopoietic Stem Cells
;
Hematoxylin
;
Humans
;
Immunohistochemistry
;
Mesenchymal Stromal Cells
;
Methods
;
Organoids
;
Regenerative Medicine
;
Stem Cells
;
Umbilical Cord
;
Vimentin